论文部分内容阅读
1968年研究发现,阿司匹林有抗血小板聚集作用,这一发现在80年代经过对自愿者和动脉粥样硬化患者的观察证明,20～40mg/d剂量就能达到这一作用。临床证据表明这一发现也可应用于严重血管疾患的高危病人,但在对阿司匹林的有效剂量,尤其是对脑缺血病人的剂量方面仍有争论。 20世纪70年代,在加拿大首次进行了阿司匹林预防卒中有效剂量的试验,为1300mg/d。到1990年,抗血小板聚集试验的人数超过7万人。阿司匹林常用剂量为75mg～325mg/d,此范围的剂量在预防血管病方面的作用基本相似,无迹象表明大剂量
1968 study found that aspirin anti-platelet aggregation, the findings in the 1980s after the volunteers and atherosclerosis observed in patients with 20 ~ 40mg / d dose to achieve this effect. Clinical evidence suggests that this finding can also be applied to high-risk patients with severe vascular disease, but there are still controversies regarding the effective dose of aspirin, especially for patients with cerebral ischemia. In the 1970s, the first effective aspirin stroke prevention trial in Canada was at 1300 mg / day. By 1990, the number of anti-platelet aggregation tests exceeded 70,000. Aspirin commonly used dose of 75mg ~ 325mg / d, the scope of the dose of the prevention of vascular disease in the role of similar, no signs of high doses